Education
About Us
Working with TipRanks
Follow Us
Fresenius Se (FSNUY)
:FSNUY
Top Page
Fresenius SE & Co
(OTC:FSNUY)
Rating:73Outperform
Price Target:
$13.50
▲(6.55%Upside)
Fresenius SE & Co (FSNUY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$27.98B
Dividend Yield1.46%
Average Volume (3M)36.36K
Price to Earnings (P/E)63.0
Beta (1Y)0.22
Revenue Growth-19.78%
EPS GrowthN/A
CountryUS
Employees175,202
SectorHealthcare
Sector Strength41
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.24
Shares Outstanding2,252,949,200
10 Day Avg. Volume10,699
30 Day Avg. Volume36,360
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)5.04
Price to Sales (P/S)0.00
P/FCF Ratio58.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$14.13Price Target Upside11.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Fresenius SE & Co Business Overview & Revenue Model
Company DescriptionFresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
How the Company Makes MoneyFresenius SE & Co. generates revenue through multiple streams across its business segments. Fresenius Medical Care, the largest segment, earns income primarily by providing dialysis care and selling dialysis products such as machines and related consumables to healthcare providers. Fresenius Helios operates hospitals, earning revenue from patient care services, while Fresenius Kabi generates income through the sale of pharmaceuticals and medical devices, focusing on infusion therapies and clinical nutrition. Fresenius Vamed contributes by managing healthcare facilities and providing technical services. The company's revenue is supported by a combination of direct patient services, product sales, and healthcare infrastructure management, with strategic partnerships and acquisitions enhancing its market presence and financial performance.
Fresenius SE & Co Earnings Call Summary
Earnings Call Date:May 07, 2025
(Q1-2025)
| % Change Since: 6.47%|
Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment Positive
The earnings call highlighted a strong start to 2025 with significant achievements in EPS growth, business momentum in Kabi and Helios, and strategic deleveraging. However, challenges such as the absence of energy relief in Germany, potential U.S. tariff impacts, and market challenges in China were noted.Q1-2025 Updates
Positive Updates
Strong Start to 2025
Fresenius reported a strong start to 2025 with excellent momentum across its businesses and reconfirmed its full-year guidance.
Double-Digit EPS Growth
The company achieved a double-digit EPS growth, reflecting efforts in turning around the company with a 12% increase in core EPS performance in the first quarter.
Kabi's Strong Performance
Kabi delivered strong top line growth driven by biopharma, with an EBIT margin increase to 16.8% and organic revenue growth of 6%.
Helios' Encouraging Start
Helios had an encouraging start to the year with organic revenue growth of 8% and Helios Spain achieving a 13.1% EBIT margin.
Deleveraging and Balance Sheet Strength
The company reduced its leverage to 3x net debt to EBITDA and aims to further strengthen the balance sheet with proceeds from the divestment of Fresenius Medical Care.
Biopharma Momentum
Biopharma showed significant momentum with 40% organic top line growth and profitability improvements.
Negative Updates
Absence of Energy Relief in Germany
Helios Germany's EBIT margin was impacted by the absence of energy relief, though it improved sequentially.
Impact of U.S. Tariffs
Potential ramifications from recent trade and tariff policies could affect future economic activity, although Fresenius believes it can navigate these challenges.
China Market Challenges
The Keto VVP impact in China is expected to start in the second quarter, with a low to mid-double-digit revenue impact.
Company Guidance
In the Q1 2025 earnings call, Fresenius reported a strong start to the fiscal year, reaffirming its full-year guidance. Key metrics highlighted include a 7% organic top-line growth and 4% EBIT growth at constant currency, alongside a significant 12% increase in EPS due to improved capital deployment and portfolio optimization. Kabi achieved a notable EBIT margin of 16.8%, propelled by its growth vectors, particularly in biopharma, which is nearing its structural EBIT margin range of 16% to 18%. Helios also showed robust performance, with Helios Spain achieving a 13.1% EBIT margin, while Helios Germany continues to focus on process efficiencies. The company has tightened its leverage target to a corridor of 2.5 to 3.0 net debt over EBITDA, ending the first quarter within this range. Additionally, Fresenius highlighted the successful sale of Fresenius Medical Care shares, which contributed to its strategic flexibility and balance sheet strength.Fresenius SE & Co Financial Statement Overview
Summary
Fresenius SE & Co's financial health is underscored by solid operational margins and an effective balance sheet structure, supported by strong cash flow management. However, challenges in net income margins and erratic revenue growth affect the score.Income Statement
The income statement reveals a mixed performance. Gross profit margin for TTM (Trailing-Twelve-Months) is healthy at 24.48%, and EBIT margin is 8.65%, indicating operational efficiency. However, the net profit margin is modest at 1.91%, highlighting challenges in translating revenue into profit. Revenue growth has been erratic, with a decline in recent years, affecting overall score.65
Positive
Balance Sheet
The balance sheet shows strength in equity with an equity ratio of 44.91%. The debt-to-equity ratio stands at 0.70, suggesting a balanced capital structure. However, the return on equity (ROE) is low at 2.17%, indicating limited effectiveness in generating returns on invested capital.70
Positive
Cash Flow
The cash flow statement is robust, with a strong operating cash flow to net income ratio of 6.19, indicating effective conversion of income into cash. Free cash flow growth is notable, and the free cash flow to net income ratio is 3.95, highlighting efficient cash management practices. Nevertheless, recent fluctuations in free cash flow growth suggest potential volatility.72
Positive
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 22.11B | 21.83B | 22.30B | 40.84B | 37.52B | 36.28B | Gross Profit |
| 5.41B | 5.38B | 5.06B | 10.72B | 10.31B | 10.32B | EBIT |
| 1.91B | 1.78B | 1.14B | 3.51B | 4.16B | 4.38B | EBITDA |
| 3.24B | 3.14B | 2.73B | 3.09B | 6.84B | 7.19B | Net Income Common Stockholders |
| 422.00M | 471.00M | -594.00M | 1.37B | 1.82B | 1.71B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 2.53B | 2.05B | 2.56B | 2.35B | 2.75B | 2.00B | Total Assets |
| 43.21B | 43.55B | 45.28B | 76.42B | 71.96B | 66.65B | Total Debt |
| 13.63B | 13.58B | 15.83B | 27.76B | 27.16B | 25.91B | Net Debt |
| 11.24B | 11.53B | 13.54B | 25.59B | 24.55B | 24.08B | Total Liabilities |
| 23.14B | 23.26B | 25.63B | 44.20B | 42.67B | 40.62B | Stockholders Equity |
| 19.41B | 19.54B | 19.00B | 20.41B | 19.00B | 16.95B |
| Cash Flow | Free Cash Flow | ||||
| 1.67B | 1.52B | 3.32B | 2.28B | 3.03B | 4.14B | Operating Cash Flow |
| 2.61B | 2.45B | 4.46B | 4.20B | 5.08B | 6.55B | Investing Cash Flow |
| -517.00M | -510.00M | -3.19B | -2.61B | -2.82B | -3.01B | Financing Cash Flow |
| -676.00M | -2.18B | -1.38B | -1.60B | -1.45B | -3.12B |
Fresenius SE & Co Technical Analysis
Positive
12.67
Price Trends
11.38
Positive
10.60
Positive
9.76
Positive
Market Momentum
0.31
Negative
66.89
Neutral
85.46
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FSNUY, the sentiment is Positive. The current price of 12.67 is above the 20-day moving average (MA) of 12.08, above the 50-day MA of 11.38, and above the 200-day MA of 9.76, indicating a bullish trend. The MACD of 0.31 indicates Negative momentum. The RSI at 66.89 is Neutral, neither overbought nor oversold. The STOCH value of 85.46 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FSNUY.
Fresenius SE & Co Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $16.73B | 25.02 | 4.36% | 2.02% | ― | ― | |
73 Outperform | $27.98B | 62.95 | 6.23% | 1.46% | -19.78% | ― | |
71 Outperform | $15.78B | 11.36 | 38.12% | ― | -1.79% | -41.85% | |
70 Outperform | $12.15B | 10.62 | 18.35% | 0.42% | 9.73% | 51.87% | |
68 Neutral | $12.22B | 25.04 | 25.33% | 0.54% | 11.21% | 30.38% | |
64 Neutral | $10.32B | 13.63 | 260.92% | ― | 5.11% | 14.28% | |
54 Neutral | $5.28B | 3.29 | -45.38% | 2.80% | 16.77% | -0.08% |
* Healthcare Sector Average
Performance Comparison
FSNUY
Fresenius SE & Co
12.67
4.60
57.00%
DVA
DaVita
137.74
-5.44
-3.80%
FMS
Fresenius Medical Care
28.65
7.72
36.88%
EHC
Encompass Health
121.29
37.03
43.95%
THC
Tenet Healthcare
171.84
38.11
28.50%
UHS
Universal Health
189.09
2.31
1.24%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.